Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.74 |
| ▸ | ERN1 | O75460 | 5/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | PRF1 | P14222 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30197394 | 1.00 | CYP2A6 (0.74) | CYP2A6ERN1PTPN1PIM3PIM1 | |
| SCHEMBL2022637 | 0.85 | CYP2A6 (1.00) | CYP2A6ERN1PTPN1PIM3PIM1 | |
| SCHEMBL21187253 | 0.80 | CYP2A6 (0.54) | CYP2A6ERN1CA2ALDH1A1PRF1 | |
| SCHEMBL1121640 | 0.78 | CYP2A6 (0.56) | CYP2A6ERN1PTPN1CA2 | |
| SCHEMBL1121724 | 0.78 | CYP2A6 (0.56) | CYP2A6ERN1PTPN1CA2ALDH1A1 | |
| SCHEMBL6811378 | 0.77 | CYP2A6 (0.50) | CYP2A6CA2ALDH1A1 | |
| SCHEMBL6811377 | 0.77 | CYP2A6 (0.50) | CYP2A6CA2ALDH1A1 | |
| SCHEMBL25232594 | 0.76 | CYP2A6 (0.46) | CYP2A6CA2ALDH1A1MIF | |
| SCHEMBL30445252 | 0.76 | CYP2A6 (0.46) | CYP2A6CA2ALDH1A1MIF | |
| SCHEMBL17912642 | 0.74 | CYP2A6 (0.61) | CYP2A6ERN1PTPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115626890-B | Diamine monomer with bulky alkynyl side group, and preparation method and application thereof | 波米科技有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-115626890-A | Diamine monomer with bulky alkynyl side group and preparation method and application thereof | 波米科技有限公司 | 2023-01-20 | — | — | CN | claimed |
| CN-115974762-B | Diamine monomer with bulky alkynyl side group, polybenzoxazole precursor, photosensitive resin composition and application thereof | 波米科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-115626890-B | Diamine monomer with bulky alkynyl side group, and preparation method and application thereof | 波米科技有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115974762-A | Diamine monomer with bulky alkynyl side group, polybenzoxazole precursor, photosensitive resin composition and application thereof | 波米科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115626890-A | Diamine monomer with bulky alkynyl side group and preparation method and application thereof | 波米科技有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-108250058-B | PPAR agonists and their use in the treatment of Alzheimer's disease and other diseases | 上海怡立舍生物技术有限公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2019141229-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | 上海怡立舍生物技术有限公司 | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141229-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | 上海怡立舍生物技术有限公司 | 2019-07-25 | — | — | WO | disclosed |
| US-9993459-B2 | Selective HDAC6 inhibitors and uses thereof | UNIVERSITEIT GENT (BE) | 2018-06-12 | — | — | US | disclosed |
| US-9993459-B2 | Selective HDAC6 inhibitors and uses thereof | UNIVERSITEIT GENT (BE) | 2018-06-12 | — | — | US | disclosed |
| US-20170360748-A1 | SELECTIVE HDAC6 INHIBITORS AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2017-12-21 | — | — | US | disclosed |
| US-20170360748-A1 | SELECTIVE HDAC6 INHIBITORS AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2017-12-21 | — | — | US | disclosed |
| US-20170360748-A1 | SELECTIVE HDAC6 INHIBITORS AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2017-12-21 | — | — | US | disclosed |
| WO-2016110541-A1 | SELECTIVE HDAC6 INHIBITORS AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016110541-A1 | SELECTIVE HDAC6 INHIBITORS AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2016-07-14 | — | — | WO | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360748-A1 | SELECTIVE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | CYP2A6 4402/4885ERN1 2959/4885PTPN1 2399/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | CYP2A6 39/4885ERN1 2132/4885PTPN1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.